Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 2

Sponsor Class

OTHER 1NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 33Breast 25Thoracic 13CNS 10Sarcoma 9Head & Neck 9Genitourinary 7Gynecologic 6Dermatologic 3Endocrine 2Other solid neoplasm 1Other 1

Conditions

Pheochromocytoma 1Multiple Endocrine Neoplasia Type 1 1Infertility 1Adrenal Gland Neoplasms 1

Interventions

Everolimus 25Magnetic Resonance Spectroscopy 13pembrolizumab 12pasireotide 12Sunitinib 11Octreotide 11lanreotide 10cabozantinib 10lenvatinib 8Sorafenib 8Cisplatin 8Temozolomide 7Etoposide 7Bevacizumab 7pazopanib 6Paclitaxel 6Nivolumab 6Doxorubicin 6Carboplatin 6Capecitabine 6vandetanib 5gallium Ga 68 dotatate 5Specimen Handling 5trametinib 4lutetium Lu 177 dotatate 4dabrafenib 4Mitotane 4Iodine-131 4telotristat ethyl 3surufatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Surgical Procedures, Operative × Endocrine × Clear all
NCT01348698 2018-11-26

Evaluation of Molecular Markers in Adrenal Tumors

National Institutes of Health Clinical Center (CC)

Terminated
74 enrolled 10 charts
Endocrine

Adrenal Gland Neoplasms, Pheochromocytoma

NCT00767338 2013-07-02

VIA

Yale University

Phase 3 Terminated
3 enrolled 3 charts
Endocrine

Infertility, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡